Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2022 | MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia | Mesa, Ruben; Komatsu, Norio; Gill, Harinder; Jin, Jie; Lee, Sung-Eun; HSIN-AN HOU ; Sato, Toshiaki; Qin, Albert; Urbanski, Raymond; Shih, Weichung; Zagrijtschuk, Oleh; Zimmerman, Craig; Verstovsek, Srdan | Clinical lymphoma, myeloma & leukemia | 3 | 3 | |
2022 | SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia | Verstovsek, Srdan; Komatsu, Norio; Gill, Harinder; Jin, Jie; Lee, Sung-Eun; HSIN-AN HOU ; Sato, Toshiaki; Qin, Albert; Urbanski, Raymond; Shih, Weichung; Zagrijtschuk, Oleh; Zimmerman, Craig; Mesa, Ruben A | Future oncology (London, England) | 21 | 11 | |